Dr. Charles M. Rudin

Dr. Charles M. Rudin, MD, PhD, is a nationally recognized leader in thoracic medical oncology and serves as Chief of Thoracic Oncology and Deputy Director of the Cancer Center at Memorial Sloan Kettering Cancer Center (MSKCC). He holds the Sylvia Hassenfeld Chair in Lung Cancer Research and co-directs the Druckenmiller Center for Lung Cancer Research. He received his MD and PhD from the University of Chicago Pritzker School of Medicine, completed residency and fellowship training there, and later served as founding co-Director of the Upper Aerodigestive Cancer Program at Johns Hopkins before joining MSKCC in 2013. Board-certified in Medical Oncology, Dr. Rudin provides expert care for patients with lung, tracheal, and thymic malignancies, offering both in-person and telehealth consultations.

He is internationally acclaimed for his translational research in small cell and non–small cell lung cancers. Under his leadership, the Rudin Lab has developed novel preclinical models—including patient-derived xenografts and CRISPR screens—to uncover therapeutic vulnerabilities and overcome treatment resistance. Dr. Rudin played a pivotal role in the Cancer Genome Atlas pilot project for lung cancer, helping to define genomic and immune mechanisms driving tumor progression. His research contributions include over 300 peer-reviewed publications and awards such as the NCI Outstanding Investigator Award, IASLC Lifetime Achievement Award, and NCI Director’s Service Award.

In addition to his laboratory and clinical responsibilities, Dr. Rudin is a committed educator and national advocate for lung cancer research. He chairs the NCI Small Cell Lung Cancer Research Consortium, serves on the NCI Board of Scientific Advisors, and engages actively in national and international oncology consortia. He mentors trainees at all levels, routinely delivers invited presentations at major scientific meetings, and fosters industry partnerships to advance early-phase clinical trials. Through his integrated roles in patient care, cutting-edge research, and scientific leadership, Dr. Rudin is recognized as one of the foremost experts shaping the future of thoracic oncology.